inebilizumab
Selected indexed studies
- Inebilizumab for Treatment of IgG4-Related Disease. (N Engl J Med, 2025) [PMID:39541094]
- A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. (N Engl J Med, 2025) [PMID:40202593]
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. (Lancet, 2019) [PMID:31495497]
_Worker-drafted node — pending editorial review._
Connections
inebilizumab is a side effect of
Sources
- Inebilizumab for Treatment of IgG4-Related Disease. (2025) pubmed
- A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. (2025) pubmed
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. (2019) pubmed
- Inebilizumab: First Approval. (2020) pubmed
- Inebilizumab: Short Chapter. (2012) pubmed
- Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. (2024) pubmed
- Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder. (2021) pubmed
- Inebilizumab-cdon. (2020) pubmed
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (2023) pubmed
- Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. (2022) pubmed